The phrase GLP-1 refers to glucagon like peptide 1, a hormone your body uses to signal fullness and help regulate blood sugar
First, GLP-1RAs have been shown to inhibit the expression and release of proinflammatory cytokines, such as IL-6 and TNF-, thereby inhibiting the overall inflammatory response
However, CDT requires intensive specialist input from certified lymphedema therapists, patient compliance is often suboptimal due to the demanding regimen, and long-term outcomes remain variable
[15] [16] Current UK prescribing information (SmPCs) for licensed GLP-1 receptor agonists does not list a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) as a contraindication, though individuals with such a history should discuss this with their clinician as a precautionary measure
These are preliminary research findings and not peer reviewed